Free trade agreements struck across the globe are blocking hundreds of millions of dollars in savings from generic and biosimilar competition via restrictive intellectual property and exclusivity provisions, according to an IQVIA study hosted by the International Generic and Biosimilar medicines Association.
Free Trade Deals Are Demolishing Savings
IP Restrictions Block Generic And Biosimilar Savings Worldwide
Global free trade agreements are having a detrimental effect on savings that can be achieved by using generics and biosimilars across healthcare systems worldwide, according to a new IQVIA report hosted by the IGBA.
